137 related articles for article (PubMed ID: 26589244)
1. From BILAG to BILAG-based combined lupus assessment-30 years on.
Murphy CL; Yee CS; Gordon C; Isenberg D
Rheumatology (Oxford); 2016 Aug; 55(8):1357-63. PubMed ID: 26589244
[TBL] [Abstract][Full Text] [Related]
2. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
Castrejón I; Tani C; Jolly M; Huang A; Mosca M
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-85-95. PubMed ID: 25365095
[TBL] [Abstract][Full Text] [Related]
3. Advances in the assessment of lupus disease activity and damage.
Rao V; Gordon C
Curr Opin Rheumatol; 2014 Sep; 26(5):510-9. PubMed ID: 25010438
[TBL] [Abstract][Full Text] [Related]
4. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment.
Luijten KM; Tekstra J; Bijlsma JW; Bijl M
Autoimmun Rev; 2012 Mar; 11(5):326-9. PubMed ID: 21958603
[TBL] [Abstract][Full Text] [Related]
5. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.
Isenberg DA; Rahman A; Allen E; Farewell V; Akil M; Bruce IN; D'Cruz D; Griffiths B; Khamashta M; Maddison P; McHugh N; Snaith M; Teh LS; Yee CS; Zoma A; Gordon C
Rheumatology (Oxford); 2005 Jul; 44(7):902-6. PubMed ID: 15814577
[TBL] [Abstract][Full Text] [Related]
6. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
7. The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus.
Marks SD; Pilkington C; Woo P; Dillon MJ
Rheumatology (Oxford); 2004 Sep; 43(9):1186-9. PubMed ID: 15226518
[TBL] [Abstract][Full Text] [Related]
8. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
[TBL] [Abstract][Full Text] [Related]
9. Which outcome measures in SLE clinical trials best reflect medical judgment?
Thanou A; Chakravarty E; James JA; Merrill JT
Lupus Sci Med; 2014; 1(1):e000005. PubMed ID: 25396057
[TBL] [Abstract][Full Text] [Related]
10. Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures.
Thanou A; James JA; Arriens C; Aberle T; Chakravarty E; Rawdon J; Stavrakis S; Merrill JT; Askanase A
Lupus Sci Med; 2019; 6(1):e000365. PubMed ID: 31921432
[TBL] [Abstract][Full Text] [Related]
11. The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index.
Devilliers H; Bonithon-Kopp C; Jolly M
Lupus; 2017 Apr; 26(4):396-402. PubMed ID: 27587460
[TBL] [Abstract][Full Text] [Related]
12. Assessment of lupus: where are we now?
Hay E; Gordon C; Emery P
Ann Rheum Dis; 1993 Mar; 52(3):169-72. PubMed ID: 8484667
[TBL] [Abstract][Full Text] [Related]
13. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000.
Yee CS; Isenberg DA; Prabu A; Sokoll K; Teh LS; Rahman A; Bruce IN; Griffiths B; Akil M; McHugh N; D'Cruz D; Khamashta MA; Maddison P; Zoma A; Gordon C
Ann Rheum Dis; 2008 Jun; 67(6):873-6. PubMed ID: 17519277
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
Ward MM; Marx AS; Barry NN
J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation.
Gladman DD; Goldsmith CH; Urowitz MB; Bacon P; Bombardier C; Isenberg D; Kalunian K; Liang MH; Maddison P; Nived O
J Rheumatol; 1994 Aug; 21(8):1468-71. PubMed ID: 7983648
[TBL] [Abstract][Full Text] [Related]
16. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.
Hay EM; Bacon PA; Gordon C; Isenberg DA; Maddison P; Snaith ML; Symmons DP; Viner N; Zoma A
Q J Med; 1993 Jul; 86(7):447-58. PubMed ID: 8210301
[TBL] [Abstract][Full Text] [Related]
17. Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.
Goteti K; French J; Garcia R; Li Y; Casset-Semanaz F; Aydemir A; Townsend R; Mateo CV; Studham M; Guenther O; Kao A; Gastonguay M; Girard P; Benincosa L; Venkatakrishnan K
CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):180-195. PubMed ID: 36350330
[TBL] [Abstract][Full Text] [Related]
18. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus.
Stoll T; Stucki G; Malik J; Pyke S; Isenberg DA
Ann Rheum Dis; 1996 Oct; 55(10):756-60. PubMed ID: 8984942
[TBL] [Abstract][Full Text] [Related]
19. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.
American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383
[TBL] [Abstract][Full Text] [Related]
20. Assessment of disease activity in Systemic Lupus Erythematosus: Lights and shadows.
Ceccarelli F; Perricone C; Massaro L; Cipriano E; Alessandri C; Spinelli FR; Valesini G; Conti F
Autoimmun Rev; 2015 Jul; 14(7):601-8. PubMed ID: 25742757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
